Article and Video CATEGORIES

Cancer Journey

Search By

Assistant Professor of Medicine, Hospital of the University of Pennsylvania, and the Veteran’s Administration Medical Center

RET/MET/BRAF: initial treatment, acquired resistance, Q&A Joshua Sabari, MD Joshua Bauml, MD
Author
Joshua Bauml, MD, Advisory Board Member, GRACE Faculty
Image

From the Targeted Therapies Patient Forum 2019, Dr. Joshua Bauml and Dr. Joshua Sabari discuss RET, MET and BRAF, the initial treatment and acquired resistance.

 

To join the conversation, visit https://cancergrace.org/forum.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora